MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
